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ABSTRACT
Background/aims Human grading of digital images
from diabetic retinopathy (DR) screening programmes
represents a significant challenge, due to the increasing
prevalence of diabetes. We evaluate the performance of
an automated artificial intelligence (AI) algorithm to
triage retinal images from the English Diabetic Eye
Screening Programme (DESP) into test-positive/technical
failure versus test-negative, using human grading
following a standard national protocol as the reference
standard.
Methods Retinal images from 30 405 consecutive
screening episodes from three English DESPs were
manually graded following a standard national protocol
and by an automated process with machine learning
enabled software, EyeArt v2.1. Screening performance
(sensitivity, specificity) and diagnostic accuracy (95% CIs)
were determined using human grades as the reference
standard.
Results Sensitivity (95% CIs) of EyeArt was 95.7%
(94.8% to 96.5%) for referable retinopathy (human
graded ungradable, referable maculopathy, moderate-to-
severe non-proliferative or proliferative). This comprises
sensitivities of 98.3% (97.3% to 98.9%) for mild-to-
moderate non-proliferative retinopathy with referable
maculopathy, 100% (98.7%,100%) for moderate-to-
severe non-proliferative retinopathy and 100%
(97.9%,100%) for proliferative disease. EyeArt agreed
with the human grade of no retinopathy (specificity) in
68% (67% to 69%), with a specificity of 54.0% (53.4%
to 54.5%) when combined with non-referable
retinopathy.
Conclusion The algorithm demonstrated safe levels of
sensitivity for high-risk retinopathy in a real-world
screening service, with specificity that could halve the
workload for human graders. AI machine learning and
deep learning algorithms such as this can provide
clinically equivalent, rapid detection of retinopathy,
particularly in settings where a trained workforce is
unavailable or where large-scale and rapid results are
needed.
Diabetic eye disease is a microvascular complication
of Type 1 and Type 2 diabetes, and is a leading cause
of incident blindness in people of working age. Early
detection through screening programmes for
diabetic retinopathy (DR) with digital retinal ima-
ging can reduce the impact of this condition.1
National screening programmes for DR, including
the National Health Service (NHS) Diabetic Eye
Screening Programme (DESP), represent a major
challenge to healthcare providers. The incidence
and prevalence of diabetes mellitus are increasing;
425 million adults were estimated by the
International Diabetes Federation to be living with
diabetes in 2017, a prevalence that has doubled
since 1980 and is projected to rise to 629 million
by 2045.2 Screening for DR is generally based on
human grading, which is labour intensive, requiring
human graders, who should be trained, undergo
regular quality assurance and be retained. Applying
the current UK annual screening protocol globally
would require 2.2 billion retinal images to be graded
in 2030. Emerging automated retinal image analysis
systems (ARIAS) are artificial intelligence (AI)
(machine learning) algorithms3 4 that may provide
cost-effective alternatives to human grading,
designed to have a high sensitivity for detection of
sight-threatening retinopathy in need of clinical
intervention. These systems could be used to triage
those who have sight-threatening DR or other ret-
inal abnormalities, from those at low risk of sight-
threatening retinopathy.
This study expands on our previous study pub-
lished in 2016–20175 6 that quantified the screening
performance and diagnostic accuracy of three
ARIAS using NHS DESP human grading as
a reference standard. Two of the ARIAS achieved
acceptable sensitivity when compared with human
graders and had specificities that made them cost-
effective alternatives to human grading alone. We
reported how such software could be incorporated
into pre-existing screening pathways6 and that
replacement of a primary human grader was the
most cost-effective strategy, compared with
a strategy that used the ARIAS as a filter prior to
primary human grader (figure 1 shows the pathway
on which cost-effectiveness analyses were
performed.6)
This study provides a large prospective evaluation
using an updated version of one of the ARIAS in
three current DESPs conducted in North East
London (NEL), South East London (SEL) and
Gloucestershire (GS) during a different time period
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to the first study. Therefore, different populations with diabetes,
different human grading teams and different cameras are contri-
buting to this evaluation of a single algorithm. In its current form,
the ARIAS is not considered precise enough to be a diagnostic test
capable of replacing human grading altogether. The updated
version of the ARIAS evaluated in this study has now received
CE marking (Conformité Européene marking indicates that it is
compliant with European Union product legislation and meets
safety, health or enviromental requirements) and is in its final
stages of Food and Drug Administration evaluation. However, no
large independent evaluation on a UK or other screening popula-
tion has yet been undertaken. The aim of this study is to evaluate
whether the ARIAS is sensitive and specific enough to successfully
triage patients into low- and medium-/high-risk DR cases,
thereby potentially reducing the need for all screening episodes
to receive human grading, allowing resources to be focused on
high-risk screening episodes. Hence, the aim is to evaluate ARIAS
in combination with manual grading, rather than to replace all
manual grading.
METHODS
Three screening programmes contributed to the study, DESPs of
NEL, GS and SEL. Programme activity and patient demographic
characteristics for the 2017–2018 period are presented in table 1.
The rate of uptake of the screening invitation ranged from 77%
to 83%. Sex differences were similar, with more men being
screened in each centre reflecting the predominance of males
with diabetes. There was a higher proportion of Asian and black
patients screened within the London centres, which reflects the
local population with diabetes.
In the current screening pathway, all retinal images are reviewed
by a primary grader, and any patients with mild or worse retino-
pathy or maculopathy (in addition to the 10% graded ‘no
retinopathy’) are reviewed by a secondary grader, with discrepan-
cies between the primary and secondary grader reviewed by an
arbitration grader (tertiary grader).7 A sample size commensurate
with our previous work5 6 was sought. Hence, our target was to
obtain retinal images from approximately 10 000 consecutive
screening episodes at each centre that had been graded for retino-
pathy level by the local team of graders as part of standard care. At
least two digital image fields were taken of each eye, one centred on
the optic disc and the other on themacula, in accordance withNHS
Figure 1 Decision tree model used to calculate the incremental cost-effectiveness of human grading versus replacing initial grading undertaken by
human graders (primary graders) with automated retinal image analysis systems (ARIAS).5 6 The clinical practice pathway as illustrated reflects the
pathway and grading23 that was used in previous cost-effectiveness analyses.5 6 Non-referable retinopathy refers to human grades of no observable
retinopathy (R0) and mild-to-moderate non-proliferative retinopathy (R1) and non-referable maculopathy (M0). Referable retinopathy refers to referable
maculopathy (M1), moderate-to-severe non-proliferative retinopathy (R2) and proliferative retinopathy (R3) and ungradable images (U).8 9 DESP,
Diabetic Eye Screening Programme; DR, diabetic retinopathy.
Table 1 Activity and patient characteristics across three screening
centres for the 2017–2018 period
NEL DESP GS DESP SEL DESP
Number of patients invited 106 257 30 658 77 086
Number of patients examined
(participation rate %)
88 519 (83%) 23 697 (77%) 62 738 (81%)
Ethnicity of patients (%)
White 35.8 66.9 50.8
Asian 43.0 2.5 13.2
Black 15.4 1 26.3
Mixed 1.2 0.5 2.1
Not-specified 4.6 29.3 7.6
Gender
Male (%) 54 57 54.4
Female (%) 46 43 45.6
Not specified (%) <0.1 <0.1
Age
Mean (range) in years 60 (12–107) 66 (12–104) 61 (12–107)
50 years or older (%) 79.5 87.1 83.3
DESP, Diabetic Eye Screening Programme; GS, Gloucestershire; NEL, North East London; SEL,
South East London.
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DESP protocol.8 Images that were of poor quality or classified as
ungradable by human graders were included in the data set. The
data set included all images captured for each eye for each episode,
including partial retinal images, poor quality images and non-
retinal images such as cataracts. Hence, this study analysed 30
000 real live episodes with images captured as part of routine
clinical care without any editing or selection of images prior to
processing with ARIAS, EyeArt. Research Governance approval for
the study was obtained. Images were pseudonymised, and no
change in the clinical pathway occurred.
The CE-marked software complied with relevant European
legislation, EyeArt v2.1.0 (Eyenuk, Woodland Hills, CA), was
used to assess retinal images for each person for the presence of
DR. The software was installed on 3 January 2017 on two servers
within a secure computer facility at the Homerton Hospital.
Pseudo-anonymised image data were brought to the secure com-
puter facility from the three sites using encrypted disks and pro-
cessed. Images from NEL were processed on 14 January 2017,
from SEL 6 February 2017 and from GS 25 April 2017. The
patient clinical pathway was not affected by the processing of
images by the machine learning algorithm as this process was
undertaken in parallel with usual care. The human grade for
each image was not available while the images were being pro-
cessed by the EyeArt software. EyeArt classification for the pre-
sence of retinopathy for each person was either test-positive or
test-negative. Episodes with images found to be un-assessable, that
is, technical failure by the software, were allocated as test-positive,
on the basis that these cases would need further human assessment.
The human grading was undertaken in each programme
using NHS DESP guidelines.8 9 The final human grade in
the worst eye was used as the reference standard for all
analyses presented. We have previously shown that the final
human grade is a stable reference standard since measures of
screening performance and accuracy of performance metrics
were not materially altered when the reference standard was
further refined by arbitration by an expert reading centre.5 6
Human grading classifications were, no observable retinopa-
thy (R0), mild-to-moderate non-proliferative retinopathy
(R1), non-referable maculopathy (M0), ungradable images
(U), referable maculopathy (M1), moderate-to-severe non-
proliferative retinopathy (R2) and proliferative retinopathy
(R3). The commensurate ETDRS retinopathy grade scores
are as follows9 10: R0 equivalent to ‘no apparent retinopathy’;
R1 ETDRS scores 20–35 inclusive; R2 ETDRS scores 43–53
inclusive; R3 ETDRS scores 61+. A more detailed description
of NHS DESP grades alongside ETDRS final retinopathy
grade is available.9 In the English DESP, retinopathy grades
R0M0, R1M0 are non-referable retinopathy and grades M1,
R2 and R3 are referable retinopathy. Patients with ungradable
images are referred for slit-lamp biomicroscopy within the
DESP. Patients with referable retinopathy are then referred
to the hospital eye service. Patients with non-referable retino-
pathy receive an invitation for re-screening within 1 year.
Statistical analysis
All analyses were performed using STATA 15.0 IC (STATACorps
LP, College Station, TX USA). Estimates of screening perfor-
mance and diagnostic accuracy were determined (sensitivity/
detection rate, false-positive rates, specificity) and the corre-
sponding 95% CIs for each centre and overall were also deter-
mined. Screening performance estimates are given for each grade
separately as well for referable versus non-referable retinopathy.
Logit-transformed 95% CIs were determined or binomial exact
CIs in the presence of detection rates of 100%. Systematic differ-
ences between centres in the likelihood of screening outcome
being classified as test-positive versus test-negative, conditional
on human retinopathy grade, were examined using a χ2 test.
RESULTS
The number of consecutive screening episodes with complete
human grading are given in table 2 for each centre and overall.
Each centre contributed at least 10 000 consecutive screening epi-
sodes. The prevalence of different retinopathy grades was similar in
NEL and SEL with marginally lower prevalence of retinopathy
grades R1M1, R2 and R3 (and consequently a higher proportion
of R1M0 and R0M0) in GS compared with the other two centres.
The proportion of screening episodes that were ungradable ranged
from 1.9% in GS DESP up to 3% at the NEL DESP.
Table 3 presents the EyeArt classification of test-negative
and test-positive for each screening episode by centre and
overall. For episodes manually graded as R0M0 (no retino-
pathy), the specificity (EyeArt classification of test-negative)
overall is about two-thirds, ranging from 65% in SEL to 71%
in GS. A high proportion (from 84% to 93%) of those with
mild-to-moderate non-proliferative retinopathy and no-
referable maculopathy (human grade R1M0) were classified
as test-positive by EyeArt software. All cases of moderate-to-
severe non-proliferative retinopathy and proliferative retino-
pathy (human grades R2 and R3, with or without macular
involvement) were detected by the software as test-positive or
‘technical failure’, that is, a sensitivity of 100%.
Table 4 provides measures of diagnostic accuracy in terms of
the 95% confidence limits (CI) around the estimates for each
centre and overall for episodes classified as test-positive (includ-
ing technical failures) by the software.
The sensitivity (95% CIs) of EyeArt was 95.7% (94.8% to
96.5%) for referable retinopathy (human graded ungradable,
referable maculopathy, moderate-to-severe non-proliferative or
proliferative: grades U, M1, R2 and R3). This figure is composed
of sensitivities of 98.3% (97.3% to 98.9%) for mild-to-moderate
non-proliferative retinopathy with referable maculopathy
(R1M1), 100% (98.7% to 100%) for moderate-to-severe non-
Table 2 Prevalence of retinopathy based on the final human grade in
the worst eye for each centre and for all three centres combined
Final human
retinopathy
grade
Number of episodes in each DESP
(column %)
NEL GS SEL
Combined
(column %)
R0M0 7031 (69.4%) 6867 (68.1%) 7414 (72.9%) 21 312 (70.1%)
R1M0 2252 (22.2%) 2645 (26.2%) 1994 (19.6%) 6891 (22.7%)
R1M1 368 (3.6%) 287 (2.8%) 346 (3.4%) 1001 (3.3%)
R2 127 (1.3%) 50 (0.5%) 113 (1.1%) 290 (1%)
R2M0 38 (0.4%) 24 (0.2%) 31 (0.3%) 93 (0.3%)
R2M1 89 (0.9%) 26 (0.3%) 82 (0.8%) 197 (0.6%)
R3 57 (0.6%) 49 (0.5%) 66 (0.6%) 172 (0.6%)
R3M0 28 (0.3%) 23 (0.2%) 20 (0.2%) 71 (0.2%)
R3M1 29 (0.3%) 26 (0.3%) 46 (0.5%) 101 (0.3%)
Ungradable 302 (3%) 193 (1.9%) 244 (2.4%) 739 (2.4%)
Total 10 137 10 091 10 177 30 405
Retinopathy grades: No retinopathy (R0); mild-to-moderate non-proliferative retinopathy
(R1); non-referable maculopathy (M0); ungradable images (U); referable maculopathy (M1),
moderate-to-severe non-proliferative retinopathy (R2) and proliferative retinopathy (R3).8 9
DESP, Diabetic Eye Screening Programme; GS, Gloucestershire; NEL, North East London; SEL,
South East London.
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proliferative retinopathy (R2), and 100% (97.9 to, 100%) for
proliferative disease (R3) (table 4).
For non-referable retinopathy (human grade R1M0), 89.1%
(88.4% to 89.9%) were classified as test-positive (this is the
sensitivity/detection rate for non-referable retinopathy).
EyeArt agreed with the human grade of no retinopathy
(R0M0) in 68% (67% to 69%). Hence, the specificity for no
retinopathy (test-negative) is 68%; the equivalent expressed as
a false-positive rate is 32.1% (31.5% to 32.7%) (table 4). If this
group is considered in combination with non-referable retinopa-
thy (R1M0), the specificity is 54% (53.4% to 54.5%) (equivalent
to 46.0% (45.5% to 46.6%) expressed as a false-positive rate),
which is the specificity corresponding to the detection rate of
95.7% for referable retinopathy given above.
Approximately 50% (15 091/30 405) of all screening episodes
would require further human grading after EyeArt classification
and this percentage ranged from 47% to 51% across the three
centres.
The EyeArt likelihood ratio for a test-positive result for refer-
able disease was stable across centres. There was some evidence of
variation across the three centres in the proportion of episodes
classified as test-negative for screening episodes with human
retinopathy grades no retinopathy (R0M0) or mild-to-moderate
non-proliferative retinopathy with no-referable maculopathy
(R1M0) (interaction p<0.001). However, the maximum abso-
lute difference in specificity between centres was only 3.6 percen-
tage points.
DISCUSSION
This prospective study has demonstrated the high sensitivity of an
AI-enabled algorithm to detect referable DR across three differ-
ent UK screening centres, with a diverse ethnic mix of individuals
with diabetes. Among 30 405 screening episodes, all 462 cases of
moderate-to-severe non-proliferative retinopathy (human grade
R2) and proliferative DR (human grade R3) were classified by
EyeArt as test-positive (including technical failures) and would
Table 3 Screening performance of EyeArt software compared with the final human grade in the worst eye for each centre and for all three centres
combined
EyeART classification (row % within each centre)
Final human
grade
NEL GS SEL Combined (row %)
Test-negative Test-positive
Test-
negative
Test-
positive
Test-
negative
Test-
positive
Test-
negative
Test-
positive
Retinopathy grades
R0M0 4787 (68.1%) 2244 (31.9%) 4891 (71.2%) 1976 (28.8%) 4793 (64.6%) 2621 (35.4%) 14 471 (67.9%) 6841 (32.1%)
R1M0 184 (8.2%) 2068 (91.8%) 431 (16.3%) 2214 (83.7%) 133 (6.7%) 1861 (93.3%) 748 (10.9%) 6143 (89.1%)
R1M1 4 (1.1%) 364 (98.9%) 8 (2.8%) 279 (97.2%) 5 (1.4%) 341 (98.6%) 17 (1.7%) 984 (98.3%)
R2 0 (0%) 127 (100%) 0 (0%) 50 (100%) 0 (0%) 113 (100%) 0 (0%) 290 (100%)
R2M0 0 (0%) 38 (100%) 0 (0%) 24 (100%) 0 (0%) 31 (100%) 0 (0%) 93 (100%)
R2M1 0 (0%) 89 (100%) 0 (0%) 26 (100%) 0 (0%) 82 (100%) 0 (0%) 197 (100%)
R3 0 (0%) 57 (100%) 0 (0%) 49 (100%) 0 (0%) 66 (100%) 0 (0%) 172 (100%)
R3M0 0 (0%) 28 (100%) 0 (0%) 23 (100%) 0 (0%) 20 (100%) 0 (0%) 71 (100%)
R3M1 0 (0%) 29 (100%) 0 (0%) 26 (100%) 0 (0%) 46 (100%) 0 (0%) 101 (100%)
U 29 (9.6%) 273 (90.4%) 22 (11.4%) 171 (88.6%) 27 (11.1%) 217 (88.9%) 78 (10.6%) 661 (89.4%)
Total 5004 5133 5352 4739 4958 5219 15 314 15 091
Retinopathy grades: No retinopathy (R0); mild-to-moderate non-proliferative retinopathy (R1); non-referable maculopathy (M0); ungradable images (U); referable maculopathy (M1), moderate-to
-severe non-proliferative retinopathy (R2) and proliferative retinopathy (R3).8 9
GS, Gloucestershire; NEL, North East London; SEL, South East London.
Table 4 Screening performance measures along with 95% confidence limits for each centre and for all three centres combined
Final human grade
Percentage classified as test-positive (including technical failure) by EyeArt (95% CI)*
NEL GS SEL Combined
R0M0 31.9 (30.8, 33.0) 28.8 (27.7, 29.9) 35.4 (34.3, 36.4) 32.1 (31.5, 32.7)
R1M0 91.8 (90.6, 92.9) 83.7 (82.2, 85.1) 93.3 (92.1, 94.3) 89.1 (88.4, 89.9)
R1M1 98.9 (97.1, 99.6) 97.2 (94.5, 98.6) 98.6 (96.6, 99.4) 98.3 (97.3, 98.9)
R2* 100.0 (97.1, 100.0) 100.0 (92.9, 100.0) 100.0 (96.8, 100.0) 100.0 (98.7, 100.0)
R2M0 100.0 (90.7, 100.0) 100.0 (85.8, 100.0) 100.0 (88.8, 100.0) 100.0 (96.1, 100.0)
R2M1 100.0 (95.9, 100.0) 100.0 (86.8, 100.0) 100.0 (95.6, 100.0) 100.0 (98.1, 100.0)
R3* 100.0 (93.7, 100.0) 100.0 (92.7, 100.0) 100.0 (94.6, 100.0) 100.0 (97.9, 100.0)
R3M0 100.0 (87.7, 100.0) 100.0 (85.2, 100.0) 100.0 (83.2, 100.0) 100.0 (94.9, 100.0)
R3M1 100.0 (88.1, 100.0) 100.0 (86.8, 100.0) 100.0 (92.3, 100.0) 100.0 (96.4, 100.0)
U 90.4 (86.5, 93.3) 88.6 (83.2, 92.4) 88.9 (84.3, 92.3) 89.4 (87.0, 91.5)
*95% CIs are binomial exact.
Retinopathy grades: No retinopathy (R0); mild-to-moderate non-proliferative retinopathy (R1); non-referable maculopathy (M0); ungradable images (U); referable maculopathy (M1), moderate-to
-severe non-proliferative retinopathy (R2) and proliferative retinopathy (R3).8 9
GS, Gloucestershire; NEL, North East London; SEL, South East London.
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have been sent for human grading. Using the EyeArt system to
triage screening episodes (rather than replace manual grading
altogether) could halve the workload for human graders. This
report used a methodology framework for independent perfor-
mance evaluation5 that could be applied to future evaluations of
other algorithms developed for this purpose.
Strengths of the current study include the large sample size,
based on patients from real-world screening environments within
three current DESPs, and evaluated independently of any com-
mercial partner. Although there was a small difference in the
performance of the EyeArt software across the three centres,
mainly in terms of specificity for non-referable retinopathy, this
is not surprising given there will be systematic differences
between the three DESPs in terms of the patient- and centre-
specific characteristics, such as age, ethnicity profiles (fundus
pigmentation may influence software performance)5, quality of
image capture and variation in human grading (ie, random error
or systematic grader-bias), which is more common with lower
grades of retinopathy.11 Although our previous work has shown
that screening performance of two ARIAS appeared to be robust
to variations in age, ethnicity and camera type, this was only
within oneDESP, which is likely to show less variation than across
different DESPs.5 6 It is noteworthy that detection rates were high
and likelihood ratios for referable retinopathy were stable across
centres. The sensitivity of EyeArt is high for detection of sight-
threating retinopathy and exceeds any published AI algorithm to
date.12 Importantly, the specificity is sufficient to make an even
greater cost-saving to the NHS than previously described.5
Automated screening software, including recent developments
using machine learning, has been available for some time,13 but
independent, large-scale validation of commercially available
licences14 has been limited until recently.5 6 Population screening
programmes have not routinely used automation for retinopathy
detection, with the exception of the Scottish national programme,
which uses a computer program to triage macula-centred images
(one per eye) into presence or absence of disease.15 However, in
our previous work, we showed that this system could not operate
on disc-centred images as part of the English DESP.5
The methods previously described5 have been adopted by
other groups, when validating new approaches to automated
assessment of retinal images.16 This latter work tested the algo-
rithm on a data set of over 10 000 retinal images. Our current
work tests the software on over 120 000 retinal images (30 000
screening episodes with a minimum of four retinal images per
episode and on average five images per patient).
A recent evaluation of this software on the EyePACS telescre-
ening programme by the software developer achieved lower
levels of sensitivity for referable DR of 91% vs 95.7% in the
current study, but with higher levels of specificity of 91% for
‘non-referable retinopathy’.17 Differences in EyeArt perfor-
mance between this study and ours are likely to result from
differing software thresholding cut-offs being implemented as
well as differences in image capture systems, image quality and
human grading. Hence, there is an ongoing need to evaluate such
systems locally to evaluate the impact on estimates of screening
performance of any ARIAS.
Diabetes is recognised as a health challenge for every country.
Good glycaemic and blood pressure control reduce the risk of
incident diabetic eye disease, but regular screening for DR is
necessary to detect sight-threatening diabetic eye disease so that
appropriate treatment can be given to prevent vision loss. The UK
has one of the largest, systematic DESPs in the world, with well-
documented procedures to train and quality assure human gra-
ders. However, there are recognised variations in the ability of
different countries and healthcare models to provide screening
and treatment for sight-threatening complications of DR.
The majority of those with diabetes will have a very low
risk of vision loss (either no retinopathy or mild non-
proliferative retinopathy). Performance of human graders
can vary at this end of the spectrum, without harming the
patient. This is because an image with no retinopathy or an
image with a single microaneurysm (mild retinopathy) will
have the same outcome for the patient, that is, a routine
review in 1 year (in the UK), or even less frequently in
some countries with longer screening intervals for low-risk
disease. Nonetheless, vast numbers of grading hours are
devoted to this repetitive task, reducing the time available
for grading high-risk images. Machines can address the pro-
blem of repeated grading. We have shown one such machine-
learning software could halve the amount of DR screening
images requiring human grading without missing sight-
threatening disease.
Two other measures of screening performance worth mention-
ing are the positive predictive value and negative predictive value.
Among all test-positive results from EyeArt, the probability of
any retinopathy was 55% and 14% had referable retinopathy
according to human grading. Among all test-negative results
from EyeArt when compared with human grader, 94.5% did
not have any observable retinopathy, 99% did not have referable
retinopathy.
A previous version of the software (v1) with poorer specificity
was shown to considerably reduce the cost of screening.5 6 Figure 1
demonstrates the clinical screening pathways that were in use at
that time, and the associated cost-effectiveness analysis evaluated
a potential strategy of implementing ARIAS into the screening
pathway by replacing the primary grader. Hence, all test-positive
results from ARIAS (~50% of all screened) would immediately
pass to the secondary grader. This is unlikely to result in an
increased workload for the secondary grader, because in the exist-
ing fully manual grading pathways we have observed, between
40% and 50% of all screening episodes pass from the primary to
the secondary grader across the three NHS DESPs included in this
study. In addition, about 10% pass to the tertiary grader for
arbitration. Under the proposed pathway, only screening episodes
classified at test-negative by the ARIAS but as referable retinopathy
by the secondary grader would pass to tertiary grader for arbitra-
tion. In reality, this will be a small proportion, since only 10% of
test-negatives pass to the secondary grader, of which its estimated
that 1.7% (tables 3, 4) would include potentially referable disease.
This would equate to approximately 50 cases per 30 000 screening
episodes. Hence, the workload for the tertiary (arbitration) grader
would reduce. The implementation of ARIAS as outlined in the
figure could potentially save £0.5 million per 100 000 screening
episodes, offering huge savings in relation to over 2.2 million
screening episodes per year (2017–2018) in England alone, with
numbers increasing.18 We also demonstrated that this was more
cost-effective than using the ARIAS as a filter prior to human
grading by level 1 graders.5 6 The performance of the software
(v2.1.0) in this current study has improved since the original report
and we expect, therefore, that the cost savings will also have
improved.
The number of people diagnosed with diabetes globally is esti-
mated at 625 million by 2045,2 which would generate between 2
and 3 billion retinal images per year following an English screening
programme approach. Current evaluations predict that diabetes-
associated blindness is likely to rise dramatically in the developing
world.19 Given the numbers of people with diabetes, costs and
quality of eye carewill become evenmore important. The use of AI
Heydon P, et al. Br J Ophthalmol 2020;0:1–6. doi:10.1136/bjophthalmol-2020-316594 5
Clinical science
 o
n
 July 7, 2020 by guest. Protected by copyright.
http://bjo.bmj.com/
Br J O
phthalm
ol: first published as 10.1136/bjophthalmol-2020-316594 on 30 June 2020. Downloaded from 
represents a new avenue for DR screening,13 16–20 and the use of
neural networks has also demonstrated promise in staging DR and
triaging other retinal conditions.21 22 This technology could be
extended to screening programmes in developed and developing
nations. The potential for nearly instantaneous triage at the point
of image capture has not yet been fully explored but is another area
where this technology could enhance diabetes eye care. Integration
of ARIAS with OCT (for detection of macular oedema) at image
capture is another potential pathway. All systems should undergo
rigorous independent evaluation before changes are made to exist-
ing DR screening pathways.
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